What Ferring does

Ferring Pharmaceuticals is a privately held, family-controlled specialty biopharmaceutical company founded in 1950 and headquartered in Saint-Prex, Switzerland. The company develops and commercializes prescription medicines across four therapeutic areas — reproductive medicine and maternal health, gastroenterology, urology and uro-oncology, and microbiome therapeutics — serving patients with significant unmet medical needs such as couples facing infertility (1 in 6 globally), patients with BCG-unresponsive non-muscle invasive bladder cancer, individuals with inflammatory bowel disease, and those suffering from recurrent C. difficile infection. Ferring employs more than 7,500 people across 50+ countries, operates R&D centers in 10 countries, and is contributing to approximately 500,000 IVF/ART-conceived births per year through its product portfolio.

The company's technology platform spans peptide hormone analogues (e.g., the vasopressin analogue MINIRIN for nocturia), recombinant protein and monoclonal antibody development, an intravesical gene-based therapy platform (ADSTILADRIN / nadofaragene firadenovec-vncg, the first gene therapy approved for BCG-unresponsive NMIBC), and a microbiota-based therapeutics franchise anchored by Rebyota for recurrent C. difficile infection. Flagship product Menopur leads the reproductive medicine franchise, while more than 60% of research investment is concentrated in women's reproductive medicine and maternal health — areas where competitor investment has historically been thin. The active pipeline includes 13 ongoing clinical trials enrolling 5,000 patients in reproductive and maternal health, supplemented by emerging initiatives in AI-driven ultrasound imaging biomarkers (partnership with IAG/DYNAMIKA) and a 70-country Gallup-partnered Global Fertility Monitor data initiative.

Ferring generated over €2.5 billion in revenue in 2025 (10% growth year over year), driven primarily by Menopur and the US ramp-up of ADSTILADRIN. The go-to-market model relies on a global direct field-sales and medical-science-liaison network reaching fertility clinics, hospitals, and urology practices across 50+ countries, augmented by distributor partnerships in developing markets and a direct consumer/employer engagement layer through initiatives like #ProjectFamily. Pricing is not publicly disclosed and is set by healthcare systems and insurers, with recurring-revenue economics for therapies such as ADSTILADRIN (administered every three months). The company is currently executing the Enterprise Model restructuring — eliminating up to 500 positions globally (64 at the Parsippany US HQ through July 2026) and reorganizing into two business units — while exploring strategic options for Rebyota and continuing to invest in gene therapy, fertility, and next-generation microbiome platforms.

Name

Ferring

Legal name

Ferring International Center S.A.

Website

https://ferring.com

Company type

Private

Founded year

1950

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Ferring Pharmaceuticals is a privately held Swiss specialty biopharmaceutical company that develops and commercializes prescription medicines in reproductive medicine, maternal health, gastroenterology, urology, and uro-oncology, with products such as Menopur and the gene therapy ADSTILADRIN serving patients in 50+ countries.

Ownership category

akta.pro rank

Product category

Specialty Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Gastroenterology Specialty Pharmaceuticals (HLAIACAE), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

Keywords

• Reproductive medicine pharmaceuticals
• Fertility treatment drugs
• Gene therapy oncology
• Gastroenterology medications
• Maternal health therapeutics

Headquarters

HQ city

Saint-prex

HQ country

Switzerland

HQ region

Europe

Offices18 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Ferring generates revenue through the sale of prescription pharmaceutical products across reproductive medicine, gastroenterology, urology, and uro-oncology. Revenue exceeded €2.5 billion in 2025, representing 10% growth from 2024, driven primarily by flagship product Menopur and ramp-up of gene therapy Adstiladrin in the US.
2. Gene Therapy (Adstiladrin): Adstiladrin is administered once every three months for bladder cancer treatment, providing recurring revenue from ongoing treatment cycles.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Ferring is a specialty biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines in reproductive medicine and maternal health, gastroenterology, urology, and uro-oncology. Its portfolio spans peptide hormones, gene therapies, and live biotherapeutic microbiome products sold under established brands such as Menopur, Endometrin, PENTASA, MINIRIN, Rebyota, and ADSTILADRIN to physicians, fertility clinics, hospitals, and specialty pharmacies in roughly 50 countries.

Product overview

Ferring Pharmaceuticals is a specialty biopharmaceutical group committed to helping people build families and live better lives. The company operates across four core therapeutic areas: Reproductive Medicine & Maternal Health, Gastroenterology, Urology & Uro-Oncology, and Microbiome. Key products include Menopur (flagship fertility treatment), ADSTILADRIN (gene therapy for bladder cancer), PENTASA (for inflammatory bowel disease), and MINIRIN (for nocturia). Ferring has a strong heritage in reproductive medicine with products like Bravelle and Novarel, and is expanding into uro-oncology gene therapy. The company also develops microbiome-based therapeutics including Rebyota for C. difficile infection. Ferring's research focuses on fertility treatments, preterm birth prevention, postpartum hemorrhage reduction, and bladder cancer, with AI-driven imaging collaborations for personalized fertility care.

Differentiator

Problem solved

Functional benefit

Brands

• Adstiladrin: Gene-based therapy (nadofaragene firadenovec-vncg) for high-risk BCG-unresponsive non-muscle invasive bladder cancer
• Rebyota
• Menopur
• Bravelle
• Novarel
• Endometrin
• PENTASA
• MINIRIN
• #ProjectFamily
• Building Families at Ferring
• MIRAI Review

Products and services

• ADSTILADRIN (nadofaragene firadenovec-vncg) Intravesical adenoviral vector-based gene therapy indicated for high-grade BCG-unresponsive non-muscle invasive bladder cancer, administered by urologists and oncology centers.
• Menopur (menotropins) Highly purified menotropin (hMG) used for controlled ovarian stimulation in women undergoing assisted reproductive technology such as IVF. Prescribed by reproductive endocrinologists.
• Endometrin (progesterone) Vaginal progesterone insert used for luteal phase support in women undergoing fertility treatment, including IVF cycles.
• Novarel (chorionic gonadotropin, hCG) Human chorionic gonadotropin product used to trigger final follicular maturation and ovulation in women undergoing fertility treatment.
• Bravelle (urofollitropin) Highly purified follicle-stimulating hormone (urofollitropin) used for ovarian stimulation in women undergoing assisted reproductive technology.
• PENTASA (mesalamine) Oral and rectal mesalamine (5-ASA) formulations used for the induction and maintenance of remission in mild-to-moderate ulcerative colitis, prescribed by gastroenterologists.
• MINIRIN (desmopressin) Desmopressin acetate used to treat conditions including primary nocturnal enuresis, diabetes insipidus, and nocturia associated with nocturnal polyuria in adults.
• Rebyota (fecal microbiota, live-jslm) First FDA-approved live biotherapeutic (fecal microbiota, live-jslm / RBX2660) for the prevention of recurrence of Clostridioides difficile infection in adults following standard-of-care antibiotic treatment.

Quantifiable outcome

• 500,000 babies born each year thanks to IVF and ART treatments supported by Ferring products
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

13 partnerships are on record, tiered core and minor.

• GallupcoreStrategic or Co-development Partner · 16 April 2026Collaboration to launch Ferring Global Fertility Monitor, tracking factors influencing fertility choices. The study will collect nationally representative data from 70 countries through Gallup World Poll starting in 2027, representing one of the most comprehensive global databases on parenthood aspirations.
• Theralase TechnologiescoreStrategic or Co-development Partner · 9 January 2026Clinical development agreement to investigate combination therapy for BCG-unresponsive non-muscle invasive bladder cancer. The study combines Theralase's Ruvidar (light-activated small molecule) with Ferring's Adstiladrin gene therapy, enrolling patients in the US with potential expansion to Canada. Theralase plans to complete enrollment by Q1 2026 and follow-up by Q2 2027.
• Posterity HealthcoreStrategic or Co-development Partner · 1 June 2024Partnership to launch male fertility program aimed at educating men and encouraging earlier fertility evaluations alongside their partners, addressing male fertility market gaps.
• BII Holdings A/ScoreStrategic or Co-development Partner · 1 April 2023Strategic partnership with Danish biotechnology startup to accelerate innovation in women's health and reproductive medicine, specifically addressing historical underinvestment in female-specific healthcare areas through support for early-stage projects and startups.
• SK PharmtecocoreStrategic or Co-development PartnerPartnership to expand production of Adstiladrin gene therapy to meet growing demand for the bladder cancer treatment.
• Image Analysis Group (IAG)coreTechnology or IntegrationAI imaging collaboration using IAG's DYNAMIKA platform to develop imaging biomarkers from real-world ultrasound data from Fertility Centers of Illinois and Dexeus Barcelona. Project aims to validate predictive AI models for identifying optimal conception timing and create regulator-ready endpoints for fertility clinical trials.
• March of DimescoreStrategic or Co-development PartnerCollaboration on preterm birth research through prematurity research network, focusing on areas of high unmet need in maternal health.
• World Health Organization (WHO)coreStrategic or Co-development PartnerPartnership to help prevent post-partum haemorrhage (PPH), addressing the leading direct cause of maternal mortality.
• MSD for MotherscoreStrategic or Co-development PartnerPartnership to help prevent post-partum haemorrhage, combining resources to reduce maternal mortality globally.
• Karolinska InstitutetcoreStrategic or Co-development PartnerResearch collaboration on preterm birth focusing on areas of high unmet need in reproductive medicine.
• Fertility Matters at WorkminorGTM or Marketing PartnerCollaboration on workplace fertility research and awareness campaign to support employees undergoing fertility treatment.
• This Can Happen GlobalminorGTM or Marketing PartnerPartnership on international survey highlighting emotional, financial, and career impact of fertility treatment, urging employers to adopt inclusive policies.
• UNFPAcoreStrategic or Co-development PartnerFerring is a proud champion of UNFPA's Coalition for Reproductive Justice in Business, aiming to embed reproductive health into corporate strategy.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Organon & Co. US-listed specialty pharma spun out of Merck focused on women's health, reproductive medicine, and established brands; competes directly with Ferring in fertility (e.g., Ganirelix) and shares similar endocrinology/urology adjacencies.
• Merck KGaA (Healthcare): German life sciences company whose Healthcare division leads the global fertility market with Gonal-f and other reproductive medicines, directly competing with Ferring's Menopur and Bravelle in IVF.
• Ipsen: French specialty pharma with a meaningful uro-oncology franchise (Tepadina, Decapeptyl/Trelstar) overlapping Ferring's urology and uro-oncology therapeutic areas, particularly in bladder and prostate cancer.
• Astellas Pharma: Japanese pharma with the leading uro-oncology drug Padcev (enfortumab vedotin) for urothelial cancer and ongoing prostate cancer work, directly comparable to Ferring's Adstiladrin franchise in NMIBC.
• UCB: Belgian specialty pharma focused on immunology and neurology with Cimzia competing in inflammatory bowel disease; broadly comparable mid-cap specialty profile and therapeutic overlap in gastroenterology.
• Endo International: US specialty pharma historically active in urology/endocrinology and women's health, with overlapping therapeutic interests (nocturia, hormone therapies, men's health) and similar specialty-pharma business model.

Broad incumbents

• AbbVie: Large pharma with a major gastroenterology franchise (Humira, Skyrizi, Rinvoq for IBD), competing with Ferring's Pentasa in inflammatory bowel disease and serving overlapping physician specialties.
• Takeda Pharmaceutical: Large Japanese pharma operating across gastroenterology (Entyvio for IBD) and women's health adjacencies; comparable to Ferring in scale of specialty prescription sales and therapeutic breadth.
• Pfizer: Largest US pharma with broad franchises in oncology, inflammation, and reproductive/urology adjacencies; comparable only as a broad incumbent where Ferring competes for physician share in oncology/IBD.

Emerging players

• Seres Therapeutics: US microbiome therapeutics company with Vowst (first FDA-approved oral microbiome therapy) for recurrent C. difficile, the same indication as Ferring's Rebyota, making it a direct emerging competitor in microbiome therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/ferringpharmaceuticals
• Instagraminstagram.com/ferringpharmaceuticals
• Xx.com/ferring
• LinkedInlinkedin.com/company/ferring-pharmaceuticals

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ferring